<DOC>
	<DOCNO>NCT01644097</DOCNO>
	<brief_summary>This randomized phase II clinical trial study probiotic supplementation prevent treatment-related diarrhea patient cancer undergo chemotherapy . Probiotics may help prevent diarrhea cause treatment chemotherapy .</brief_summary>
	<brief_title>Probiotic Supplementation Preventing Treatment-Related Diarrhea Patients With Cancer Undergoing Chemotherapy</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Incidence moderate/severe ( grade 2-4 ) diarrhea grade accord Common Terminology Criteria Adverse Events ( CTCAE ) version 4.0 . II . Functional Assessment Chronic Illness Therapy - Diarrhea ( FACIT-D ) Trial Outcome Index . SECONDARY OBJECTIVES : I . To evaluate effect probiotic supplementation dose delay reduction due gastrointestinal ( GI ) toxicity . II . To evaluate effect probiotic supplementation anti-diarrheal medication use . III . To evaluate effect probiotic supplementation overall health-related quality life ( HR-QOL ) . IV . To evaluate effect probiotic supplementation febrile neutropenia . V. To evaluate effect probiotic supplementation adverse GI effect . VI . To evaluate effect probiotic supplementation overall survival . VII . To evaluate effect probiotic supplementation progression free survival . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive mixture Lactobacillus plantarum strain 299v , Bifidobacterium lactis probiotic supplement , Lactobacillus acidophilus probiotic orally ( PO ) twice daily ( BID ) 9 week . Treatment continue absence unacceptable toxicity . ARM II : Patients receive placebo PO BID 9 week . Treatment continue absence unacceptable toxicity . After completion study treatment , patient follow 4 week every 3 month .</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<criteria>Any patient document malignancy initiate treatment include ( single agent combination drug ) one follow cancer therapeutic : Fluorouracil ( 5FU ) , capecitabine , irinotecan , paclitaxel , docetaxel , cabazitaxel , crizotinib , sorafenib , sunitinib , erlotinib , lapatinib Any pathologically confirm malignancy patient would receive listed cancer therapeutic Performance status Eastern Cooperative Oncology Group ( ECOG ) 02 Patient must estimate life expectancy least 6 month Absolute neutrophil count ( ANC ) &gt; 1500 Platelets &gt; 100K Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) &lt; 2.5 x ULN ( upper limit normal ) Serum bilirubin &lt; 1.5 x ULN Serum creatinine &lt; 1.5 x ULN Ability understand willingness sign write informed consent document comply treatment protocol Patients currently undergo treatment list therapeutic time initiation trial ; patient prior treatment ( ) one agent initiate new treatment another agent list , provide least 2 week `` washout '' period Patients currently take antidiarrheal medication therapy Patients undergoing hemodialysis Patients know allergic hypersensitivity reaction probiotic , yoghurt , similar diet supplemental product Acute chronic diarrhea , include lactose intolerance , gluten dietary sensitivity result gastrointestinal symptom Pregnant nursing patient Known human immunodeficiency virus ( HIV ) positive Prior abdominal surgery result stoma , ostomy , fistula , anatomic defect Concurrent near future radiotherapy ; prior , complete radiotherapy allow ; radiotherapy within vicinity GI tract must complete least 4 week prior start trial Treatment investigational drug within 4 week prior enrollment Current treatment antibiotic gut motility agent within 2 week start study medication Abnormal thyroid function control medication Patients take dietary supplement within 2 week start study medication Any serious uncontrolled illness , opinion investigator , make undesirable patient enter trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Quality Life</keyword>
</DOC>